These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 29557749)

  • 1. Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.
    Maiese K
    Curr Neurovasc Res; 2018; 15(1):81-91. PubMed ID: 29557749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer.
    Maiese K
    Curr Neurovasc Res; 2017; 14(3):299-304. PubMed ID: 28721811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss.
    Maiese K
    Curr Neurovasc Res; 2017; 14(4):415-420. PubMed ID: 29149835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive Impairment and Dementia: Gaining Insight through Circadian Clock Gene Pathways.
    Maiese K
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegeneration, memory loss, and dementia: the impact of biological clocks and circadian rhythm.
    Maiese K
    Front Biosci (Landmark Ed); 2021 Sep; 26(9):614-627. PubMed ID: 34590471
    [No Abstract]   [Full Text] [Related]  

  • 6. Forkhead transcription factors: new considerations for alzheimer's disease and dementia.
    Maiese K
    J Transl Sci; 2016 Jul; 2(4):241-247. PubMed ID: 27390624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease.
    Maiese K
    Curr Neurovasc Res; 2017; 14(1):82-88. PubMed ID: 27897112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes.
    Maiese K
    Curr Neurovasc Res; 2020; 17(5):765-783. PubMed ID: 33183203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.
    Maiese K
    Biochem Soc Trans; 2018 Apr; 46(2):351-360. PubMed ID: 29523769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.
    Maiese K
    Br J Clin Pharmacol; 2016 Nov; 82(5):1245-1266. PubMed ID: 26469771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.
    Maiese K
    Curr Neurovasc Res; 2021; 18(1):134-149. PubMed ID: 33397266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.
    Maiese K
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):23-34. PubMed ID: 31794280
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1.
    Maiese K
    Neural Regen Res; 2021 Mar; 16(3):448-455. PubMed ID: 32985464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk.
    Maiese K
    Front Immunol; 2023; 14():1273570. PubMed ID: 38022638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxO proteins in the nervous system.
    Maiese K
    Anal Cell Pathol (Amst); 2015; 2015():569392. PubMed ID: 26171319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT1 activation and its circadian clock control: a promising approach against (frailty in) neurodegenerative disorders.
    Ribeiro RFN; Pereira D; de Almeida LP; Silva MMC; Cavadas C
    Aging Clin Exp Res; 2022 Dec; 34(12):2963-2976. PubMed ID: 36306110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR.
    Maiese K
    Neural Regen Res; 2016 Mar; 11(3):372-85. PubMed ID: 27127460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs and SIRT1: A Strategy for Stem Cell Renewal and Clinical Development?
    Maiese K
    J Transl Sci; 2015 Nov; 1(3):55-57. PubMed ID: 26561536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus.
    Maiese K
    Curr Neurovasc Res; 2020; 17(3):327-331. PubMed ID: 32216738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.
    Maiese K
    Curr Neurovasc Res; 2017; 14(2):184-189. PubMed ID: 28294062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.